Shay Shemesh
Founder bei NUVECTIS PHARMA, INC.
Vermögen: 12 Mio $ am 31.03.2024
Profil
Shay Shemesh has founded Nuvectis Pharma, Inc. in 2020, where he currently holds the titles of Chief Development, Operations Officer & EVP.
He previously worked as Head-Clinical Operations at Keryx Biopharmaceuticals, Inc. and as Senior VP-Clinical & Regulatory Affairs at Stemline Therapeutics, Inc. from 2015 to 2020.
Mr. Shemesh has an undergraduate and graduate degree from Bar-Ilan University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NUVECTIS PHARMA, INC.
8,40% | 03.01.2024 | 1 491 955 ( 8,40% ) | 12 Mio $ | 31.03.2024 |
Aktive Positionen von Shay Shemesh
| Unternehmen | Position | Beginn |
|---|---|---|
| NUVECTIS PHARMA, INC. | Founder | 27.07.2020 |
Ehemalige bekannte Positionen von Shay Shemesh
| Unternehmen | Position | Ende |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2020 |
| KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Shay Shemesh
| Bar-Ilan University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
| Nuvectis Pharma, Inc. |
